Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PMV Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for PMV Pharmaceuticals, Inc.

PMVP

PMV Pharmaceuticals, Inc.

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals is a precision oncology company focused on developing small molecule therapies targeting p53 mutations, a common driver in over half of all cancers. Its lead candidate, rezatapopt, aims to structurally correct specific p53 mutations, such as Y220C, across multiple tumor types. The company advances tumor-agnostic, gene-specific treatments through clinical trials, leveraging genomic sequencing and targeted drug development to improve cancer patient outcomes.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PMV Pharmaceuticals, Inc.

1
1
PMV Pharmaceuticals, Inc. PMV Pharmaceuticals Reports $18M Net Loss in Q1 2026, Advances Clinical Trials for Rezatapopt

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
PMV Pharmaceuticals, Inc. PMV Pharmaceuticals Reports $77.7 Million Net Loss for 2025, Focuses on Rezatapopt Development

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
PMV Pharmaceuticals, Inc. PMV Pharmaceuticals Reports $21.1 Million Net Loss in Q3 2025, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PMV Pharmaceuticals, Inc. PMV Pharmaceuticals Reports $21.2 Million Net Loss in Q2 2025, Increases R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PMV Pharmaceuticals, Inc. PMV Pharmaceuticals Reports $17.4 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PMV Pharmaceuticals, Inc. PMV Pharmaceuticals Reports $58.7 Million Net Loss for 2024, Advances Rezatapopt in Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
PMV Pharmaceuticals, Inc. PMV Pharmaceuticals Reports Q3 Financial Results, Net Loss Improves Despite Increased R&D Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments